Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinica BavieraXMAD:CBAV -0.70%100 3-Year Book Growth Rate is 18.50% as of Jun. 2026, which is 104% above its 10-year median of 9.05. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €44.74 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 83.77% on this metric.
During the past 12 months, Clinica Baviera's average Book Value per Share Growth Rate was 23.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 18.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 21.10% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Clinica Baviera was 36.80% per year. The lowest was -46.10% per year. And the median was 9.05% per year.
Clinica Baviera (XMAD:CBAV) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Clinica Baviera 3-Year Book Growth Rate Related Terms
XMAD:CBAV vs TMO, DHR, NTRA: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's 3-Year Book Growth Rate falls into.
Clinica Baviera 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 18.50% mean?
Clinica Baviera (XMAD:CBAV) has a 3-Year Book Growth Rate of 18.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Clinica Baviera and its competitors. This is 104% above median its historical median of 9.05. According to the industry distribution chart, Clinica Baviera ranks #31 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 16.2%.
Is Clinica Baviera's 3-Year Book Growth Rate too high?
Clinica Baviera's current 3-Year Book Growth Rate of 18.50% is 104% above median its 10-year median of 9.05. Based on the distribution chart, Clinica Baviera ranks #31 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's 3-Year Book Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #31 out of 191 companies for 3-Year Book Growth Rate. This places Clinica Baviera in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Clinica Baviera and its competitors. Clinica Baviera's current 3-Year Book Growth Rate is 18.50%, which is 104% above median its own 10-year median of 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.74, compared to a current price of €56.40 — trading 26.1% above its estimated fair value. The current 3-Year Book Growth Rate is 18.50%, which is 104% above median its 10-year median of 9.05. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current 3-Year Book Growth Rate is 18.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.40 is trading 26.1% above its estimated GF Value™ of €44.74.
GuruFocus considers Clinica Baviera to be Modestly Overvalued.
Key valuation signals for XMAD:CBAV:
3-Year Book Growth Rate: 18.50% (104% above median its 10-year median of 9.05)
GF Value™: €44.74 vs. price of €56.40 (26.1% above fair value)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
